481 followers
@SciencePharmer @ChristosArgyrop @hswapnil As with everything, I believe some patients would still benefit. That being said, DKA with SGLT2i has quoted mortality of 1.4% compared to 0.4% for DKAs at large. https://t.co/wu00TQYJau
@SciencePharmer @ChristosArgyrop @hswapnil As with everything, I believe some patients would still benefit. That being said, DKA with SGLT2i has quoted mortality of 1.4% compared to 0.4% for DKAs at large. https://t.co/wu00TQYJau
RT @MediCasos: 4) 2019, Revisión de la literatura de CAD euglicemica y SGLT - 2 -> https://t.co/FYYQ4INjll
RT @MediCasos: 4) 2019, Revisión de la literatura de CAD euglicemica y SGLT - 2 -> https://t.co/FYYQ4INjll
RT @MediCasos: 4) 2019, Revisión de la literatura de CAD euglicemica y SGLT - 2 -> https://t.co/FYYQ4INjll